ClinicalTrials.gg
CompletedNCT00712114Updated Jun 14, 2011

Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis

A Phase 1/2 interventional study of HE3286 and HE3286 in Rheumatoid Arthritis, sponsored by Harbor Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-06-14.

Sponsored by Harbor Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 122 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Enrollment
695th of 771
14 · median 120
Started
2008
with 36 others
Phase 1/2
27 of 975
6 open now
Registered
234th of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 695th largest by enrollment of the 771 interventional ones that give a count, is one of 37 that started in 2008, is one of 27 in phase 1/2, and was the 234th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

The purpose of this pilot, exploratory study is to evaluate the safety, tolerance, pharmacokinetics and potential anti-inflammatory activity of an investigational agent, HE3286, when administered orally for 29 days to patients with rheumatoid arthritis that are taking a stable dose of methotrexate.

Read the detailed description

This is a Phase I/II, open label, dose ranging study of the safety, tolerance, and anti-inflammatory activity of HE3286 in patients with rheumatoid arthritis. Patients will receive study treatment (one of three open label doses) in addition to their current stable dose of methotrexate. Safety (via monitoring of vital signs, physical examination changes, ECG results, laboratory results, and adverse events), pharmacokinetics profiles (of HE3286 and methotrexate) and anti-inflammatory activity will be assessed over a treatment period of 29 days.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • phase I
  • safety
  • tolerance
  • rheumatoid arthritis
  • pharmacokinetics
  • methotrexate
  • anti-inflammatory
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Male or female patient 18-75 years of age
  • Patient with stable or active disease on a stable dose of methotrexate for at least 30 days prior to Day 1
  • Patient has normal thyroid stimulating hormone (TSH) levels with or without thyroid replacement therapy
  • Patient is willing to abstain from consuming grapefruit containing products from 24 hours prior to dosing until the end of the study as it may affect the pharmacokinetic measurements
  • Patient has not experienced renal or liver disease by history and/or based on laboratory results
  • Patient has not experienced acute cardiac disease within 6 months prior to Screening
  • Patient must provide voluntary, written, prior to screening evaluations and be able to follow verbal and written instructions.

Main Exclusion Criteria:

  • Functional status class IV according to The American College of Rheumatology (ACR) criteria
  • Patient who has a history of cardiovascular disease (including coronary artery disease), clinically significant hepatic, respiratory or renal abnormalities, or clinically significant endocrine disorders (including diabetes)
  • Patient with active Tuberculosis (TB) or evidence of latent TB without previous adequate therapy
  • Systemic disorder (including, but not limited to, systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or any overlap syndrome)
  • Inflammatory joint disease other than RA
  • Patient who has received any of the following drugs:

    • Etanercept within 1 month of Day 1;
    • Abatacept, adalimumab, infliximab, leflunomide, imuran, cyclosporin, anakinra, sulfasalazine, bextra, celebrex or gold within 2 months of Day 1 or for biological agents 6 half lives, whichever is greater;
    • Rituximab within 1 year of Day 1
  • Patient that is bed or wheelchair bound
  • Patients taking prednisone within 2 weeks prior to Screening
  • Patient requiring or receiving any of the following within thirty (30) days prior to the screening visit: interleukins, (i.e., anabolic steroids, glucocorticoids), hormone replacement therapy (except stable low-dose HRT for at least 6-months prior to screening), pills, anti-cancer chemotherapeutic agents (except methotrexate), metabolic inhibitors (except methotrexate), concomitant medications that prolong the /QTc interval
  • Patient who has any clinically significant abnormalities in laboratory results at Screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Cohort 1

    10 mg HE3286 (1 x 5 mg HE3286, BID)

    Drug: HE3286

  • Experimental
    Cohort 2

    20 mg HE3286 (2 x 5 mg HE3286 BID)

    Drug: HE3286

  • Experimental
    Cohort 3

    40 mg HE3286 (4 x 5 mg HE3286 BID)

    Drug: HE3286

Interventions

  • DrugHE3286

    HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.

    Also known as: Triolex

  • DrugHE3286

    HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days

    Also known as: Triolex

  • DrugHE3286

    HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days

    Also known as: Triolex

06

What researchers measure

Primary outcomes

  1. Safety and pharmacokinetics

    Time frame: Duration of the study

Secondary outcomes

  1. To assess the potential activity of HE3286 to decrease inflammation via evaluation of inflammatory cytokine activity.

    Time frame: Duration of study

07

Study locations

1 site
  • Beverly Hills, California 90211, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2008
First posted
Jul 9, 2008
Start
Jul 2008
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Last update
Jun 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00712114
Lead sponsor
Harbor Therapeutics
First posted
Jul 9, 2008
Start date
Jul 2008
Primary completion
Jul 2009
Completion
Jul 2009
Last update
Jun 14, 2011

Study contacts

Dwight Stickney, MD
study director · Hollis-Eden

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bezisterim

Start the discussion